NeoImmuneTech prepares for its IPO next year The company has scouted four experts and built its corporate R&D center
Translated by Kim So-in 공개 2019-11-14 08:00:00
이 기사는 2019년 11월 14일 08:00 thebell 에 표출된 기사입니다.
U.S.-based immunotherapy drug development company NeoImmuneTech is accelerating preparations for its planned initial public offering (IPO) next year. The company has recruited four experts as members of the Scientific Advisory Board (SAB).According to investment banking (IB) industry sources on November 11, NeoImmuneTech scouted Crystal L. Mackall, M.D., David Lebwohl, M.D., Debasish Roychowdhury, M.D., and Rafi Ahmed, Ph.D. as new members of SAB. The first SAB meeting was held on November 9 at the annual meeting of the Society for Immunotherapy of Cancer (SITC 2019) in Maryland, U.S.
"NeoImmuneTech has succeeded in recruiting world-renowned experts in cancer immunology this year. The company has put efforts into boosting its R&D capability with establishing its own R&D center in preparation for its listing on the Kosdaq," said a market watcher.
The drug development company plans to use Korea's technology exception policy to go public on the secondary Kosdaq market next year. The Korea Exchange (KRX) began to allow foreign companies to use the technology exception rule on the condition that they undergo stricter reviews on technological competitiveness. Foreign firms must receive 'A' rating from all two rating agencies designated by the KRX. Joint bookrunners for the IPO, Hana Financial Investment and Mirae Asset Daewoo, started the field due diligence and the company plans to go through technology assessment at the end of this year or early next year.
NeoImmuneTech established its Korea office in September to boost its R&D capability and set up a corporate R&D center at Pohang University of Science and Technology (POSTECH). The R&D center plans to expand the pipeline of Hyleukin-7™ and develop candidate material for new drugs.
IB industry views the establishment of the R&D center will play a vital role in passing its technology assessment. NeoImmuneTech had tried but failed to pass the assessment. At that time the company received 'A' rating from one of the two rating agencies, but the other agency gave 'BB' rating due to the absence of R&D center. Market views that the company has now removed its weak point.
Hyleukin-7™ , an immuno-oncology agent, is a T cell growth factor composed of a covalently linked homodimer of engineered Interleukin-7 (IL-7) molecule, biologically fused with the proprietary long-acting platform - hyFc™. IL-7 is known to be a critical factor for T cells homeostasis, acting to increase both the number and functionality of T cells. Hyleukin-7 amplifies and reinvigorates persistent T cell immunity in the treatment of patients with cancer and lymphopenia, thus providing unique opportunities for immuno-oncology (IO) combination strategies.
NeoImmuneTech added its bookrunners for its IPO next year. The company has an estimated enterprise value of 800 billion won to one trillion won. Market views the company is fairly valued amid depressed biotech sector on the Kosdaq market.
(By reporter Yang Jung-woo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [노바렉스를 움직이는 사람들]정판영 연구개발총괄, '원료 강자' 만드는 브레인
- [금융지주 해외은행 실적 점검]숨고른 하나은행 인니법인, '디지털' 내세워 재도약 채비
- [2금융권 연체 리스크]삼성카드, 내실경영 전략 효과…잠재 부실 대응은 과제
- [금융지주 해외은행 실적 점검]전북은행 PCCB, 지방금융 '글로벌 1위' 입지 강화
- [보험사 IFRS17 조기도입 명암]코리안리, 호재 된 IFRS17…킥스비율도 안정적
- [KB캐피탈 인수 10년]성장동력 무게추 '자동차금융'서 '기업·투자금융' 이동
- [보험사 IFRS17 조기도입 명암]DB손보, 새 제도서 자본력 강화 비결은
- [2금융권 연체 리스크]KB국민카드, 표면 지표 '우수'…대환에 가려진 잠재 위험
- [보험사 IFRS17 조기도입 명암]카카오페이손보, 아직은 회계관리보다 '사업확대'
- 농협 개혁의 '필요조건'